Advances in the use of hydroxyurea
Authors:
Open Access
- 1 January 2009
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2009 (1) , 62-69
Abstract
Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulating for the past 25 years. The bulk of the current evidence suggests that hydroxyurea is well-tolerated, safe, and efficacious for most patients with SCD. Hydroxyurea has proven clinical efficacy for reducing acute vaso-occlusive events including pain episodes and acute chest syndrome. Salutary effects on hematological parameters include increases in fetal hemoglobin (HbF), hemoglobin, and MCV; also significant decreases occur in WBC, ANC, reticulocytes, LDH, and bilirubin. Treatment with hydroxyurea is usually considered for patients with recurrent vaso-occlusive events, but additional indications for treatment may include laboratory markers of disease severity and evidence of chronic organ dysfunction. Ten years ago, the US Food and Drug Administration approved hydroxyurea for adult patients with clinically severe SCD; however, its use in children remains off-label. Despite the large body of evidence regarding its efficacy and safety, hydroxyurea is currently prescribed only sparingly for patients with SCD and therefore has only limited effectiveness for this disorder; barriers to its use need to be identified and overcome.Keywords
This publication has 38 references indexed in Scilit:
- Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in ChildrenPediatrics, 2008
- Hydroxyurea for Children with Sickle Cell DiseasePediatric Clinics of North America, 2008
- Mortality in sickle cell patients on hydroxyurea therapyBlood, 2005
- Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell diseaseBlood, 2004
- Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell AnemiaJAMA, 2003
- A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemiaThe Journal of Pediatrics, 2001
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early DeathNew England Journal of Medicine, 1994
- Pain in Sickle Cell DiseaseNew England Journal of Medicine, 1991
- Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.Journal of Clinical Investigation, 1984